Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02097810
Recruitment Status : Completed
First Posted : March 27, 2014
Last Update Posted : June 9, 2021
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 2, 2020
Actual Study Completion Date : June 2, 2020
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):